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Abstract
Introduction: Several studies have indicated that autoimmune and neuroinflammatory processes contribute to the
neurodegeneration of retinal ganglion cells in human glaucoma patients and in animal models. To test the involvement
of cellular immune processes in the pathophysiology of retinal ganglion cell degeneration in vivo, we carried out
adoptive transfer experiments from two independent genetic mouse models of glaucoma into normal recipient mice.
Results: Our findings indicate that transfer results in a progressive loss of retinal ganglion cells and their axons
despite normal intraocular pressure in recipient mice. Signs of pan-retinal inflammation were not detected.
Similar findings were obtained following transfer of isolated T-lymphocytes, but not after transfer of
splenocytes from immune deficient glaucomatous mice. Transferred lymphocytes were detected integrated in
the spleen and in the retinal ganglion cell layer of recipient animals, albeit at very low frequencies.
Furthermore, we observed cell-cell interaction between transferred T-cells and recipient microglia along with
focal microglial activation in recipient eyes.
Conclusion: This study demonstrates that the pathophysiology of glaucomatous degeneration in the tested animal
models includes T-cell mediated events that are capable of causing loss of healthy retinal ganglion cells.
Introduction
Glaucoma is a common progressive optic neuropathy
and the second leading cause of irreversible blindness in
the world. Approximately 60 million people in the world
suffer from the disease, and of these, 7 million are blind
[44]. Elevated intraocular pressure (IOP) is a major risk
factor for the development of glaucoma, but the sensitivity
to IOP elevation varies between individuals and a number
of pressure-independent factors clearly affect the pro-
gression of retinal ganglion cell (RGC) loss in glaucoma
[6, 34]. There is mounting evidence that glaucomatous
degeneration of the human retina involves immune
mediated processes such as the establishment of a pro-
inflammatory environment in the eye including activation
of the complement cascade [33, 50], microglial activation
and expression of MHCII molecules [17, 51, 61, 63], and
increased synthesis of pro-inflammatory cytokines such as
TNF and nitric oxide [40, 53]. Several studies have indi-
cated that the development of glaucoma is correlated
with altered autoantibody patterns in patients [4, 55],
suggesting the involvement of a systemic immune
response in the disease.
Through the study of animal models it has also be-
come apparent that induction of glaucoma in one eye in-
duces an effect in the naïve contralateral eye. Activation
of retinal micro- and macroglia commonly occurs and a
mild loss of RGC has been observed in the unmanipu-
lated second eye of mice and rats [15, 30, 47]. Infiltra-
tion of monocytes into the optic nerve has been
reported in some animal models [22] and it is conceiv-
able that glaucomatous RGC loss induced by elevated
IOP initiates a systemic immune response. It has been
shown that experimental induction of high IOP levels
provokes alteration of the autoantibody pattern [26].
During the last decade, several epitopes for which al-
tered autoantibody reactions have been demonstrated in
glaucoma patients were identified. Immunization with
those proteins such as heat shock protein 60 and 27 or
other retinal/optic nerve head related antigens can induce
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slow progressive RGC loss in rodent models [24, 57].
Those studies have demonstrated that experimental in-
duction of autoimmunity can lead to RGC loss and ap-
pears to involve T-cell mediated Fas/FasL signaling and/or
TNF activation [53, 57].
In order to demonstrate that a causal relationship exists
between a primed immune system in glaucoma and subse-
quent, IOP independent, RGC degeneration, we set out to
determine if transferred immune cells, derived from glau-
comatous animals, are capable of provoking RGC damage
in recipients. We utilized mice from two hereditary glau-
coma models (B6.Sh3pxd2bnee and B6SJL;Tg-MYOCY437H
mice) as splenocyte donors [36, 64]. Both strains are char-
acterized by elevated IOP and progressive RGC loss, but
the causative genetic defect is distinct, thereby minimizing
the probability that the effect observed in recipient mice is
specific for one model system and a direct result of the
donor’s mutation. Our data demonstrate that splenocytes
from both donor strains cause progressive loss of RGC in
normal recipient mice and that T- lymphocytes likely in-
strumental in this process. These findings provide a causal
link between previous studies demonstrating immune
activation in glaucoma [4, 17, 18, 52, 54, 55] and those
indicating that experimental induction of autoimmunity
can result in RGC loss [24, 25, 27, 28, 56–58].
Materials and methods
Animals
All animal experimentation was carried out in accord-
ance to the ARVO Statement for the Use of Animals in
Ophthalmology and Vision Research and approved by
the Institutional Animal Care and Use committee of the
University of Iowa. Mice were housed in a 12/12 h day/
night cycle and fed ad libitum.
Mice carrying a mutation in the gene encoding the
podosomal adaptor protein SH3 and PX domains 2B
(Sh3pxd2bnee, referred herein as nee) are characterized
by anterior segment dysgenesis causing elevated IOP,
followed by an early-onset, high-penetrance glaucoma
phenotype [36]. C57BL/6 mice containing the nee muta-
tion were generated by 10 generations of successive back-
crosses transferring the mutation from the originating
B10.A-H2h4/(4R)SgDvEgJ background to B6.Sh3pxd2bnee
mice. Subsequently, nee mice were intercrossed with
B6.129S7-Rag1tm1Mom/J (referred herein as Rag1−) or B6.
Cg-Tg(CAG-DsRed*MST)1Nagy/J mice (The Jackson La-
boratory) to create immunodeficient nee/Rag1− mice and
homozygote nee mice which constitutively expressing the
red fluorescent protein DsRed (nee/DsRed).
Transgenic B6SJL;Tg-MYOCY437H (referred herein as
MYOC) mice were created by crossing C57BL/6 J mice
harboring the transgene and SJL mice. Mutations in the
myocilin gene are the most common genetic cause of
glaucoma in humans [14]. Transgenic MYOC mice
express a pathogenic variant of human myocilin, which
leads to trabecular meshwork dysfunction resulting in
the development of moderately elevated IOP and pro-
gressive RGC and optic nerve axon loss [64]. Only F1
animals were used for these studies.
IOP was monitored in isoflurane sedated mice using a
TonoLab rebound tonometer (Icare, Colonial Medical
Supply, Franconia, NH) as previously described [32]. All
mice were tested and found to be free of the rd8 allele,
which causes spontaneous retinal degeneration [37].
Adoptive transfer experiments
For splenocyte transfers, seven-month-old C57BL6/J
mice (abbreviated throughout as B6, The Jackson La-
boratory, Bar Harbor, ME), two-month-old nee mice or
nee/Rag1− mice and twelve-month-old MYOC mice were
used. Immediately after euthanasia spleens were excised
and tissue was mashed gently through a 40 μm pore size
nylon cell strainer into a PBS filled petri dish (Greiner
Bio One, Monroe, NC). The cell strainer was rinsed with
cold 0.1 % BSA/PBS (both Sigma Aldrich, St. Louis,
MO) and the splenocyte suspensions were centrifuged at
1500 rpm for 5 min. The pellets were resuspended in
2 ml DMEM buffer (Gibco, Life Technologies, Grand
Island, NY) and supernatants were discarded. Cell con-
centrations were determined using a hemocytometer
and adjusted to 10×106 cells/ml. 5×106 splenocytes were
injected into recipients via the tail vein. Depending on the
background of donor animals, recipient mice were either
on a C57BL/6 J or B6:SJL background (non-transgenic F1
littermates of the crosses described above).
T- and B-cell isolation was carried out using spleno-
cytes harvested as described above. Cell pellets contain-
ing splenocytes were resuspended in 1 ml cold 0.1 %
BSA/PBS after centrifugation and diluted to a concentra-
tion of 2×106 cells in1 ml 0.1 % BSA/PBS. FITC anti-
CD3 and PE anti-CD19 antibodies and their matching
negative control antibodies (BD Biosciences, San Jose,
CA) were used for labeling prior to flow cytometry
according to the manufacturer’s protocol. Sorting of the
splenic CD19 and CD3 lymphocyte fractions was carried
out using the FACSAria II system (BD) at the University
of Iowa FACS Facility. Following several washing steps in
PBS and DMEM buffer 1.5×106 CD19+ B-lymphocytes or
1×106 CD3+ T-lymphocytes, respectively, were injected
into the tail veins of B6 recipients in a volume of 0.5 ml.
An age-matched group of naïve B6 mice (N = 7) with-
out transfer were included as additional controls in this
experiments.
DsRed positive lymphocytes were obtained from spleno-
cytes harvested from nee/DsRed or B6/DsRed mice and
processed for FACS sorting as described above, expect
that FITC anti-CD3 and BrilliantViolet421anti-CD19 anti-
bodies (both BD) were used for labeling. Again, 1.5×106
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DsRed/CD19+ or 1×106 DsRed/CD3+ lymphocytes were
adoptively transferred.
Optical coherence tomography
OCT imaging was carried out in ketamine/xylazin anes-
thetized naïve B6 control mice and nee splenocyte recip-
ients 6, 12, 18, 24, 42 and 72 days after adoptive transfer
using a Bioptigen Envisu OCT (Bioptigen, Morrisville,
NC) as described previously [46]. Briefly, OCT was set
up with an A-scan by B-scan rate of 1000 and 100 B-
scans in a rectangular volume scan with a length of
1.4 mm at a width of 1.4 mm at 0°. The gridded rect-
angle was adjusted with the papilla as center point.
Quantification of RGC and axon loss
As reported previously [11], retinas were fixed for 2 h in
4 % paraformaldehyde, dissected, and whole mounted.
Retinas were incubated overnight with a rabbit-anti
γ-synuclein primary antibody (Abnova, Walnut, CA),
followed by secondary antibody incubation with an
Alexa Fluor 488 donkey anti-rabbit (Invitrogen, Life
Technologies). From each retina a Z-series was taken
from six pre-determined mid-peripheral locations using a
Nikon Eclipse i80 confocal microscope (Nikon Instruments
Inc, Melville, NY) at 600× magnification. Images were
stacked, and γ-synuclein+ RGC were counted using the cell
counter plugin in ImageJ software by an independent ob-
server masked to the animals’ status. This approach offers
rapid identification of γ -synuclein positive RGC, although
it is conceivable that some stressed RGC down regu-
late expression of this protein which could exclude
those cells from analysis.
The distal parts of optic nerves were fixed in ½
Karnovsiky’s fixative, osmicated, and embedded in Epo-
nate resin. One μm thick sections from each optic nerve
were cut with a diamond knife on a Leica EM UC7 ultra-
microtome (Leica Microsystems Inc, Buffalo Grove, IL)
and stained with 1 % paraphenylenediamine (PPD, Sigma).
Photomicrographs were taken at 100× magnification on
an Olympus BX41 microscope (Olympus, Center Valley,
PA) and assembled. Each optic nerve was independently
examined by three investigators masked to the animals’
status and assigned a damage grade based upon the num-
ber of damaged axons, the overall organization of the
optic nerve, and the frequency of gliotic changes [11, 19].
Grades were defined as: 1 = healthy, 2 = mild damage,
no gliosis, 3 = frequent PPD stained axons and mild
gliosis, 4 = severe damage with many PPD stained axons
and gliosis, 5 = severe damage and large gliotic areas
(Additional file 1: Figure S1).
Immunostaining and Histopathology
All tissues used for immunohistochemistry for histopath-
ology were immersion fixed in 4 % paraformaldehyde.
Tissue used for sections was embedded in OCT media.
7 μm sections were obtained and either stained with
hematoxylin and eosin or processed for immunohisto-
chemistry. Primary antibodies used include rabbit
anti-Iba1 (Wako Chem, Osaka, Japan), CD3 (Rabbit
anti-mouse CD3, Abcam, Cambridge, MA) and CD19
(rat anti-mouse CD19, Abcam). Secondary antibodies
used were either goat anti-rabbit Cy3 or goat anti-rat
Alexa 488 diluted 1:300 (both life technologies). It was
also necessary to enhance the endogenous signal of
DsRed+ lymphocytes through immunohistochemical
approaches. Sections were incubated with the primary
antibody mouse-anti DsRed (St. Cruz Biotechnologies,
Dallas, TX) or rabbit-anti red fluorescent protein (Abcam)
and counterstained with DAPI (Sigma, St. Louis, MO) to
facilitate orientation.
Retinal whole mounts were preserved in 4 % parafor-
maldehyde. Retinas where preincubated in 0.3 % Triton
X-100/PBS (Sigma) for 4 h and blocked in 0.1 % BSA/
0.3 % Triton X-100/PBS for 1 h. Primary antibodies were
diluted 1:300 in 0.3 % Triton X-100/PBS and incubated
for 18 h at 4 °C. After extensive washing in PBS retinas
were incubated with the secondary antibodies (1:200 in
PBS) for three hours. Retinal wholemounts were cover-
slipped and images were taken on an Olympus BX41
microscope.
Statistics
All data were analyzed in Statistica software (Dell,
Round Rock, TX) using Student’s t-test for pairwise sig-
nificance, Tukey’s honest significant difference (HSD)
with post hoc tests (with equal and unequal N) for mul-
tiple comparisons and Kruskal Wallis test for ordinal
data. Results are considered statistically significant if
p-values are less than 0.05. All data are given as
mean ± standard deviation (SD).
Results
Adoptive transfer of splenocytes derived from mouse
models of glaucoma causes RGC loss in recipient animals
In order to test the involvement of an immunologic
component in the pathophysiology of RGC degeneration,
we carried out a classic adoptive transfer experiment.
Splenocytes were obtained from either two-month-old
nee mice or from healthy B6 animals. In nee donor ani-
mals (N = 10) morphologic abnormalities of the iridocor-
neal structures leads to a significantly elevated IOP
when compared to B6 donor mice (N = 10) of similar
age (nee: 20.2 ± 6.5 vs B6: 11.9 ± 2.5 mmHg; p = 0.000008).
At this age, retinae of nee donors remain structurally intact,
but display moderate glaucomatous damage including
thinning of the retinal ganglion cell/nerve fiber layer and a
pronounced decrease in the RGC density (nee: 951 ± 518
RGC/mm2, B6: 2394 ± 179 RGC/mm2; p = 0.000007).
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RGC densities in the recipient animals were deter-
mined two (N = 14 eyes) and four months (N = 20 eyes)
after nee splenocyte transfer. Data were compared to
those derived from mice having received splenocytes
from healthy B6 donors (N = 14 eyes) as well as to age-
matched naïve control mice i.e. no adoptive transfer
(N = 18 eyes). IOP was monitored in all recipients through-
out the study and remained in the physiological range in all
groups (average: 12.5 ± 2.7 mmHg, p > 0.06, Fig. 1b).
The transfer of splenocytes from nee donor mice into
B6 mice led to a progressive reduction of RGC numbers
in recipient animals (Fig. 1a, c). Two months after trans-
fer a statistically significant difference was not yet ob-
served, although nee splenocyte recipients displayed an
approx. 10 % decreased RGC density when compared to
naïve age-matched controls (2076 ± 316 RGC/mm2 vs.
2290 ± 254 RGC/mm2, p = 0.24). Four months after trans-
fer, nee recipient animals demonstrated 23 % RGC loss
(1778 ± 267 RGC/mm2) when compared to naïve controls
(p = 0.0001) or to animals having received splenocytes from
healthy B6 donors (2284 ± 299 RGC/mm2, p = 0.0001). At
this time-point mean RGC density in all but one nee sple-
nocyte recipient was clearly below the average values
observed in either age-matched controls or B6 splenocyte
recipients (Fig. 1c). In contrast, a decline in RGC density
was not observed in the retinas of B6 splenocyte recipients
when compared to naïve mice (p = 0.99), demonstrating
that RGC loss is not initiated by splenocyte transfer itself.
In order to confirm these findings and to rule out that
the observed effect is restricted to the nee mouse model,
Fig. 1 Effects of splenocyte transfer. a Immunohistochemical detection of RGC using gamma-synuclein immunohistochemistry in whole mounted
mouse retinae. b IOP data recorded in naïve control mice, nee splenocyte recipient animals two (2 m) and four months (4 m) after transfer, and
recipients of healthy B6 splenocyte four months after transfer. IOP in all groups remains within the physiologic range and does not significantly
differ between groups (p > 0.07). Data are given as mean ± SD. c RGC density following adoptive transfer in splenocyte recipients and naïve controls.
Splenocyte transfer from healthy B6 donors does not affect RGC density in recipient animals (N = 9) four months after transfer. In contrast,
animals having received splenocytes from nee donor mice suffer a progressive loss of RGC. Two months (2 m, N = 7) after transfer RGC
density in nee splenocyte recipients is slightly reduced, but after four months (4 m, N = 10) approximately 23 % of RGC have been lost. RGC
damage is also observed in recipient animals (N= 4) when splenocytes derived from MYOC transgenic mice are transferred. Triangles represent individual
RGC data per eye and the horizontal line designates group averages. **Recipient groups vs. naïve control (N= 7), p< 0.01; ##Recipient group vs. B6 recipient
animals, p < 0.01; §four month recipient group vs. two month recipient group, p = 0.02. d Average damage scores of optic nerves as
determined by PPD staining (1 = healthy optic nerve, 5 = severe damage). Moderate axonal damage is found in optic nerves of nee
splenocyte recipients four months after transfer. *nee recipient group vs. naïve control, p = 0.02; #nee recipient group vs. B6 recipient
animals, p = 0.02 (Kruskal Wallis test). Data are given as mean ± SD
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we repeated the experiment using splenocytes obtained
from MYOC mice, a distinct IOP-associated genetic
glaucoma mouse model. Adoptive transfer of splenocytes
from MYOC mice into B6 recipients closely recapitulates
the findings obtained using nee splenocytes. Four months
after transfer retinae in recipient animals display a RGC
density of 1798 ± 152 RGC/mm2 (N = 8 eyes), indicating a
loss of approximately 22 % when compared to naïve
control animals (p = 0.005) or B6 splenocyte recipients
(p = 0.008, Fig. 1b). Again, increased IOP in recipient
mice was not observed.
In concordance with the decline in RGC density, the
mean optic nerve damage grade after PPD staining in
nee splenocytes recipients increased from 1.55 ± 0.5
(N = 9 optic nerves) two months after transfer to 2.25 ± 0.5
(N = 10 optic nerves) after four months (Fig. 1d). This level
of damage is significantly higher than that observed in
naive age-matched control animals (1.25 ± 0.5; N = 6,
p = 0.014) or mice having received splenocytes from
healthy B6 (1.18 ± 0.4; N = 8, p = 0.014, Kruskal Wallis test).
In vivo imaging reveals no early pathogenic events in
recipients
Optical coherence tomography (OCT) and funduscopy
is routinely used in clinical ophthalmology and in animal
research to detect retinal abnormalities in vivo. To test
whether the damage observed in our model was related
to an acute inflammation event, we imaged recipients’
retinae at several time points after splenocyte transfer.
Particular attention was directed towards any signs of
uveitis, such as retinal detachments, subretinal hemorrhage,
or white linear lesions as described elsewhere [10]. Retinal
scans and funduscopy were carried out in an independent
group of nee splenocyte recipients (N = 6) 6, 12, 18, 24, 42
and 72 days after transfer and compared to naïve control
mice. Retinal folds or signs of cellular infiltrates were not
observed in any of the animals after transfer of immune
cells, regardless of the time interval after injection. More-
over, recipient animals uniformly display an undisturbed
retinal architecture and a normal appearance of the optic
nerve head, even at later stages when RGC density has
already begun to decline (Fig. 2).
T-lymphocytes promote RGC loss more vigorously than
B-lymphocytes
Following our observation that RGC loss is inducible by
adoptive transfer of splenocytes, we sought to determine
if the lymphocytes included in these preparations are
primarily responsible for the observed RGC loss in re-
cipients and, if so, whether this effect is mediated by B-
or T-cells. In order to address this question, we created
immunodeficient nee mice by crossing them with Rag1−
mice [38]. The resultant immunodeficient nee (nee/Rag1−)
lack mature T-cells or B-cells, but display the glaucomat-
ous phenotype with high IOP (25.2 mmHg) and progres-
sive RGC loss. Splenocytes were obtained from these
animals and transferred into B6 recipients (N = 6) as de-
scribed above. In addition, respective CD3 and CD19 posi-
tive cell fractions were isolated by flow cytometry from
splenocytes of nee mice or B6 donors. Recipient B6 mice
were injected with either 1×106 CD3+ T-lymphocytes, or
1.5×106 CD19+ B-lymphocytes from either nee (N = 5, ea.)
Fig. 2 Optical coherence tomography. Retinal OCT imaging demonstrating a normal retinal architecture in the peripapillary (a, b, c) and peripheral
regions (d, e, f) in both age-matched B6 naïve mice and a representative nee splenocyte recipient 12 and 72 days after transfer. No evidence for acute
infiltration or retinal detachments was identified through in vivo imaging. A thinning of the retinal ganglion cell layer (rgcl, including the nerve fiber
layer) was not yet evident 72 days after transfer, even though at that time a slight loss of RGC is observed using histochemical approaches. However
an increased reflectivity (b, c, e, f) in the rgcl was noted when nee-transfer animals and naïve mice are compared (inl: inner nuclear layer; onl: outer
nuclear layer; is/os: inner and outer photoreceptor cell segments; rpe: retinal pigment epithelium)
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or healthy B6 donor animals (N = 8, ea.). As noted following
splenocyte transfer, adoptive transfer of splenocytes or
T- or B-lymphocytes from glaucomatous mice did not
increase IOP in the recipient animals. The average
IOP of recipient mice was 12.3 ± 2.6 mmHg, similar to the
normal population average (13.5 ± 2.5, p < 0.5, Fig. 3a).
Data obtained clearly demonstrate that adoptive transfer
of splenocytes from T- and B- cell deficient nee/Rag1− do-
nors does not result in RGC loss in recipients. The RGC
density following transfer of nee/Rag1− splenocytes was
2423 ± 383 RGC/mm2, very similar to the naïve control
group (N = 7, 2290 ± 254 RGC/mm2, p = 0.84) and to ani-
mals injected with T- or B-lymphocytes from B6 donors
(p > 0.6). In contrast, mice having received purified CD3+
T-lymphocytes from nee donors displayed a RGC density
of 1831 ± 245 RGC/mm2, significantly less than those
recipients injected with CD3+ T-cells from B6 mice
(2251 ± 221 RGC/mm2, p = 0.005). In contrast, transfer
of CD19+ B-lymphocytes from nee mice only resulted
in a moderate reduction of RGC density in recipient
animals when compared to mice having received CD19+
B-lymphocytes from B6 mice (1968 ± 317 RGC/mm2 vs.
2259 ± 266 RGC/mm2, respectively, p = 0.12, Fig. 3b).
Transferred lymphocytes are observed at low frequency
in recipients’ retinae
To investigate the behavior of transferred lymphocytes
in recipient animals, a transgenic allele causing constitu-
tive expression of the red fluorescent reporter protein
DsRed was introduced into nee mice (nee/DsRed). DsRed+
lymphocytes were sorted and adoptively transferred as de-
scribed above. Extravasated DsRed+ lymphocytes were
detected in whole mounted retinas as early as 16 days
after transfer. In each eye, 10–15 DsRed+ B-lymphocytes
and fewer than 5 DsRed+ T-lymphocytes are found in ret-
inal tissue outside blood vessels in nee/DsRed lymphocyte
recipients. In contrast, DsRed+ lymphocytes were not
found in the retina of recipients of B6/DsRed T-cells at
that time. However, examination of retinal tissue obtained
at later stages (20, 28 and 42 days after injection) fre-
quently revealed the presence of a small number (<5) of
transferred DsRed+ T- and B-lymphocytes regardless of
whether they were derived from glaucomatous or healthy
donor animals.
Consequently, it appears that transferred T-lymphocytes
are able to pass the blood retina barrier and are present in
the retinal parenchyma, although at a very low frequency.
Furthermore, a dramatic increase in the number of
extravasated lymphocytes was not apparent in mice
having received adoptive transfers from glaucomatous
mice. DsRed+ cells could also be detected in blood
smears of all recipient mice shortly after transfer and
throughout the study. Transferred DsRed+ T- and B-
lymphocytes were also readily detectable in the spleens
of recipient mice where they become integrated into
the pulpa in all recipient groups (Fig. 4c-f ).
Finally, we examined longitudinal optic nerve sections,
as well as brain, liver, and cervical lymph node specimens
for the presence of transferred lymphocytes. DsRed+ cell
were not detected and examination of H&E stained sec-
tions did not reveal indications of pathological changes,
such as an influx of autologous lymphocytes in retinal
(Additional file 2: Figure S2) or other tissues in any of the
mice evaluated.
Fig. 3 T- and B-cell adoptive transfer. a IOP recordings in nee/Rag1− splenocyte recipients (n=, CD3+ and CD19+ cell recipient animals. Data indicate
that the transfer does not influence IOP and remains similar to IOP values of naïve mice. The mean IOP over all groups remains at 12.6 ± 2.8 mmHg
(p > 0.5). Data are given as mean ± SD. b RGC density in nee/Rag1− splenocyte recipients and CD19+ or CD3+ lymphocyte recipient mice 4 months after
transfer. Transfer of nee CD3+ T-lymphocytes induces a significant loss of RGC in animals (N = 5) when compared to recipients of B6 CD3+ cells (N = 8),
to B6 CD19+ lymphocyte recipients (N = 8), or to a naïve control group (N = 7, **p < 0.001). Adoptive transfer of the nee CD19+ fractions results in a
modest, but not statistically significant, reduction of RGC in recipients (N = 5, p = 0.12) when compared to the corresponding B6 CD19+ lymphocyte
recipients. Transfer of splenocytes from immunodeficient nee/Rag1− donors did not result in loss of RGC in recipients (N = 6) when compared to naïve
mice and animals having received lymphocytes from B6 donors (p < 0.84). Accordingly, RGC density is also significantly lower in nee when compared
to nee/Rag1− animals (##p < 0.001). Triangles represent individual RGC data and the horizontal line designates the group average
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Microglia become activated early and interact with
lymphocytes
One of the hallmarks of neurodegeneration, including ret-
inal degeneration, is the activation of microglia [35, 41].
As the innate immune cell of the central nervous system,
microglia strongly interface with the systemic immune
system to cause bidirectional signaling, into and out of the
CNS [42]. Hence, we examined if retinal microglia are
affected by splenocyte transfer and whether there is
evidence of their interaction with transferred cells in the
retinas of recipient mice using the microglia marker Iba1
[29]. In the healthy retina microglial cells have a highly
ramified phenotype with small soma, thin branches and a
fine network of cellular processes. An early stage of micro-
glial activation is indicated by retraction of their branches
and hypertrophic somas, whereas fully activated microglia
cells are characterized by an amoeboid shape [31]. It was
apparent that only retinae of nee lymphocyte recipients,
but not B6 lymphocyte recipients, contain a small popula-
tion of hypertrophic Iba1+ microglia with an amoeboid
shape as well as a few highly activated microglia (Fig. 5).
Those microglia that appeared to be activated are fre-
quently observed in close contact to transferred DsRed/
CD3+ cells from nee mice even if quiescent microglia are
apparent a short distance away. This interaction between
transferred lymphocytes and resident microglia is occa-
sionally accompanied by other, not yet identified, en-
dogenous cells (Fig. 5f). These observations suggest an
interaction between CD3+ T-lymphocytes and resident
microglia.
Discussion and conclusions
Findings from both clinical and laboratory studies have
firmly established that IOP independent mechanisms
contribute significantly to the pathophysiology of glau-
coma. One important feature that the glaucomatous ret-
ina shares with many other neurodegenerative diseases
is the accumulation of components of the immune sys-
tem that occurs subsequent to the onset of the disease
[21, 49]. Such neuroinflammatory processes can elicit
Fig. 4 Transferred lymphocytes infiltrate the retina and spleen. a, b Immunohistochemical detection of DsRed/CD3+ T-lymphocytes (red) derived from
(a) healthy B6 (b) nee donors in the retina of recipient mice 20 days after transfer. The presence of sporadic extravasated DsRed+/CD3+ T-lymphocytes
located either within the recipients’ RGC layer (shown in a) or epiretinally on the surface of the nerve fiber layer (shown in b) was noted in all recipients.
V = retinal vessel. c-f Infiltration of transferred DsRed+ lymphocytes into the spleen of recipient animals 28 days after injection. Integration of immune
cells obtained from nee donors was noticeably more pronounced than that of those derived from B6 donors. Notation of CD3 or CD19
in the microphotographs refers to the transferred lymphocyte fraction rather than immunohistochemical detection. DAPI was used to label nuclei
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downstream immune responses that may contribute in
important aspects to the pathology as has been described
in many neurodegenerative diseases [1, 2].
Immune processes have also been associated with the
development of glaucoma, but a causal relationship has
not yet been established. Herein, we demonstrate that
adoptive transfer of splenocytes or isolated CD3+ or
CD19+ cells obtained from mouse models of glaucoma
into normal mice results in progressive RGC loss with-
out IOP elevation in recipient animals. In contrast,
transfer of splenocytes from immune deficient glau-
comatous mice or healthy B6 donors does not result in
RGC loss. While it cannot be ruled out completely that
the observed immune response is in some way dependent
upon the genetic modification of the models used, the
finding that splenocytes from two independent genetic
models can mediate the same effect suggests that the
establishment of an immune response is a general
phenomenon that likely results from elevated IOP and
RGC degeneration. Furthermore, the observed damage in
recipient mice developed at physiological IOP levels and is
consequently independent of elevated IOP.
One important issue of the present study is that the
observed RGC loss could have occurred either as part of
autoimmune mediated nonspecific pan-retinal degener-
ation or a rapid early inflammatory event. Neither of
these scenarios is consistent with glaucoma pathophysi-
ology and consequently recipient mice were carefully ex-
amined to address these concerns. Retinas of recipient
mice were monitored noninvasively in vivo using optical
coherence tomography. Our findings demonstrate that
transfer of splenocytes from glaucomatous mice does
not result in loss of cells, which is indicated by changes
in the thickness of the appropriate layer, outside the gan-
glion cell/nerve fiber layer. We also did not observe
acute episodes of leukocyte infiltration in the retina, as
is frequently the case in uveitis [10], or in the optic
nerve, as observed in optic neuritis or during experi-
mental autoimmune encephalomyelitis [45]. Spatiotem-
poral tracking of transferred DsRed labeled lymphocytes
revealed integration into the spleen, but invariably rare
transferred immune cells have been observed in the
ganglion cell layer, regardless of the time interval
since injection. Accordingly the cell loss in recipient
mice is slow, progressive and RGC specific. As such
the observed events are consistent with glaucoma
pathology rather than those of classical immune me-
diated ocular diseases.
The retina is a part of the central nervous system and
consequently is an immune privileged tissue [16, 59].
Ocular immune privilege is physiologically maintained
by the blood/retina barrier, but microglia also modulates
the process by secretion of pro- or anti-inflammatory
cytokines. The microglial cytokine profile in turn can be
significantly influenced by signaling from lymphocytes [8].
It has recently become appreciated that T-lymphocytes
crossing the blood/retina barrier is a normal process
which occurs continuously albeit at a low rate even in
healthy eyes [9, 43]. We previously demonstrated the
presence of lymphocytes in the retinal parenchyma of
Fig. 5 Appearance of ocular microglia in recipients of B6 or nee lymphocytes. a Iba1 immunostained microglia in the whole mounted retina of
an age-matched naïve control mouse depicting quiescent, ramified microglia. Retinal microglia in recipients of (b) CD19+ and (c) CD3+ cells donated
from B6 mice appear uniformly ramified 28 days after transfer. d Horizontal sections of the optic nerve also did not reveal signs of microglial activation.
Here the optic nerve of a recipient after adoptive transfer of B6 CD19+ cell fraction is shown. Numerous activated microglia are readily identified in
recipients of (e) CD19+ or (f) CD3+ lymphocytes from nee donor mice (bottom row). Both early-stage microglial activation, indicated by hypertrophic
somatic areas (arrows in f), and highly activated microglia (arrowhead in e) were observed. g Interactions between transferred T-lymphocytes
and activated resident microglia are occasionally found. These cells are located outside the retinal vasculature (V) and are accompanied by
additional, unidentified, DAPI positive endogenous cells. h Microglial activation was not observed in the optic nerve of any recipients. Scale
bars in a-c, e-f is 50 μm and in d, h 20 μm
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eyes obtained from human glaucoma patients [17]. Our
findings in this study are congruent with these data: a very
small number of transferred T- and B-lymphocytes
derived from either control or glaucomatous mice are
detectable in the ganglion cell layer of recipient mice.
It is intriguing to speculate how adoptive transfer of
T- or B-lymphocytes can lead to the observed progres-
sive RGC loss. Our findings clearly ascribe a functional
role to CD3+ donor cells, but adoptive transfer of CD19+
cells also resulted in reduced RGC density in recipient
animals, although statistical significance was not reached.
Identification of the active lymphocyte cell type is
complicated by the slow progression of damage, re-
quiring an extended experimental period that allows
ample opportunities for cross-talk between the donated
T- or B-cells and the immune system of the recipient. Fur-
thermore, the small number of extravasated lymphocytes
in recipient retinas casts some doubt on whether RGC are
damaged directly by T-lymphocytes. While it is conceiv-
able that the steady activity of even a small number of ef-
fector T-cells could significantly degrade the number of
surviving RGC cells over the lengthy observation period,
an alternative explanation is also possible. Microglial
activation is a common response to retinal injury and
also occurs in glaucoma [5, 12]. In this study we observed
direct interaction of epiretinal T-cells with activated tissue
microglia, similar to our earlier observations in human
eye donor tissue [17], and it is possible that the neurode-
generative effect is due to the deleterious activities of
microglia that become activated due to T-cell signaling.
Microglial activation entails the release of potentially
RGC damaging substances such as TNF-α, nitric oxide
synthase-2, and Fas-ligand [62] that could compromise
the health of additional RGC [48, 57]. In this scenario, the
role of T-cells is restricted to immunologic memory and a
large number of lymphocytes within the neural retina is
not required to cause the establishment of a damaging
pro-inflammatory environment. Interestingly, a number of
studies have indicated that CNS degenerating diseases can
be exacerbated by a pro-inflammatory environment, even
if the cause of the inflammation is not directly related to
the disease. For example, systemic inflammation acceler-
ates the progression of brain inflammation and frequently
precedes relapses in multiple sclerosis patients [39, 42]. It
appears that a general pro-inflammatory environment can
enhance neuronal damage via the detrimental activities of
activated microglia. In this respect it is interesting to note
that a recent report indicated a correlation between oral
bacterial counts, microglial activation, and vision loss
in glaucoma patients [3]. Retinal microglia may also
participate in the initial establishment of the autoimmune
response. These cells are likely involved in the phagocyt-
osis of damaged RGC and in antigen presentation. Phago-
cytosed cellular debris is then loaded onto antigen
presenting MHC class II molecules, which are expressed
at high levels by microglia in the glaucomatous retina [15,
23]. T-lymphocytes may encounter the presented antigens
either during normal surveillance or following failure of
the retinal vasculature, as in the case of splinter disk
hemorrhage, a complication of glaucoma which is sig-
nificantly associated with disease progression [13].
Primed T-cells then return to the lymphoid organs
where they interact with other lymphocytes and stimu-
late the maturation of effector T-cells, which subse-
quently return to the eye to degrade additional RGC.
Thus the development of an autoimmune response fol-
lows initial damage, but establishes an IOP independent
mechanism of RGC loss.
The clinical management of glaucoma patients is all
too frequently beset by slow and gradual vision loss
that continues even at IOP below the population aver-
age [7, 20] and there are indications that the T-cell
profile in glaucoma patients is distinct from healthy
controls [60]. If secondary autoimmune events akin to
those described herein occur in glaucoma patients,
current treatment modalities are ill equipped to minimize
their detrimental effects which could explain contin-
ued or recurring episodes of vision loss in the ab-
sence of elevated IOP.
Additional files
Additional file 1: Figure S1. Representative images of PPD stained
optic nerve sections used to assess axonal damage. With increasing
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1) (B) B6 splenocyte recipient (Damage grade 2) (C) nee splenocyte
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animals and in nee splenocyte recipients, four months after transfer, are
in accordance with the retinal phenotype examined through OCT. (rgcl,
including the nerve fiber layer: inl: inner nuclear layer; onl: outer nuclear
layer; is/os: inner and outer photoreceptor cell segments). (TIFF 3627 kb)
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